Print
Email
Print Edition Stories
Regenerative medicine firms make business of creating skin
MHT's Emerging Technologies Forum: Health IT and the Cloud
Health care industry eyes iPad
Waltham-based PerkinElmer Inc. has acquired chemagen Biopolymer-Technologie AG, Germany-based maker of automated nucleic acid isolation technology with operations in Worcester, for an undisclosed amount.
According to Daniel R. Marshak, chief scientific officer and president of the emerging diagnostics unit at PerkinElmer (NYSE: PKI), the purchase is part of the company’s strategy to move deeper into the molecular diagnostics and research markets. By being able to offer the nucleic acid products, PerkinElmer will be able to better serve both businesses and researchers looking into genomics analysis, DNA identification and other areas related to DNA and RNA.
Founded in December, 1997 in Baesweiler, Germany, chemagen established its United States subsidiary, chemagen USA Inc., in Worcester in 2009.
Late last week, PerkinElmer CEO Robert Friel received restricted stock worth nearly $3 million and the option to buy about 200,000 shares, according to a filing with the Securities and Exchange Commission. Friel also received the option to buy 198,337 PerkinElmer shares. The exercise price on the stock is $26.58. The options expire in seven years.
In September, PerkinElmer sold its Illumination and Detection Solutions (IDS) business to Veritas Capital Fund III LP, a New York-based private equity firm, for approximately $500 million in cash.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
